Screener Summaries Updates Institutions Sign In More Updates › Financing › NEO Financing · Jun 15, 2026
NeoGenomics, Inc. announced the commencement of a proposed offering of convertible senior notes due 2032 to qualified… NEO Neogenomics Inc
NeoGenomics, Inc. announced the commencement of a proposed offering of convertible senior notes due 2032 to qualified institutional buyers under Rule 144A. NeoGenomics, Inc. is a biotechnology company providing precision oncology testing services.
More from Neogenomics Inc NeoGenomics reports Q3 revenue of $209 million and raises full-year guidance Oct 28, 2026 Appoints Warren Stone CEO effective Jan 4, 2027; expects Q3 revenue of $209M Oct 5, 2026 NeoGenomics, Inc. announced that Alicia Olivo, Executive Vice President, General Counsel and Business Development… Aug 11, 2026 NeoGenomics, Inc. reported second-quarter 2026 results with total revenue increasing 11% year-over-year to $202… Jul 28, 2026 NeoGenomics, Inc. finalized a civil settlement with the U.S. Department of Justice on July 20, 2026, to resolve an… Jul 22, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
